{"schema_version":"secwatch.filing_event.v1","accession":"0001808665-26-000010","form_type":"8-K","ticker":"ASRT","cik":"0001808665","company_name":"Assertio Holdings, Inc.","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.254107+00:00","generated_at":"2026-05-15T11:53:52.195242+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Assertio reports Q4 adjusted EBITDA loss of $4.1M; Rolvedon sales drop to $0.4M from $15.4M","bullets":["Rolvedon Q4 net sales $0.4M vs $15.4M YoY; sell-in in Q3 2025 covered two quarters of demand, sales under new label expected Q2 2026.","Sympazan net sales grew to $3.1M from $2.5M; Indocin flat at $5.5M.","Gross margin improved to 75% from 61% on product mix and inventory write-downs in prior year.","Adjusted EBITDA loss $4.1M vs income $3.4M last year; cash dropped to $63.4M from $93.4M in Q3.","FY2026 guidance: net product sales $110M-$125M, Adj EBITDA $28M-$40M; CEO prioritizes Rolvedon and disciplined oncology build."],"urls":{"canonical":"https://secwatch.observer/filing/0001808665-26-000010","json":"https://secwatch.observer/filing/0001808665-26-000010.json","markdown":"https://secwatch.observer/filing/0001808665-26-000010.md","text":"https://secwatch.observer/filing/0001808665-26-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808665/000180866526000010/0001808665-26-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808665/000180866526000010/asrt-20260316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:53:52.195242+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07ae5d3aeb8d14bae8acd82e9bf8a41e3bf38e66","claim":"Assertio Holdings, Inc. reported financial results for the fourth quarter ended December 31, 2025.","evidence_excerpt":"today reported financial results for the fourth quarter and full year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808665/000180866526000010/0001808665-26-000010-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"48224e40a7d4471c41839926aff890e19da6a259","claim":"Assertio Holdings, Inc. updated its the fiscal year ended December 31, 2025 guidance (initiated).","evidence_excerpt":"Assertio Reports Fourth Quarter and Full Year 2025 Financial Results Delivers FY2025 Net Product Sales and Adjusted EBITDA Above Guidance Expects Net Product Sales between $110M-$125M and Adjusted EBITDA between $28M-$40M in FY2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808665/000180866526000010/0001808665-26-000010-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2025"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}